Questions relating to drug use, dosing, and related issues in oncology are presented in this regular feature.
Consider routine use of stool softeners
Use mild laxatives as needed Peripheral neuropathy 1, 3 Can become irreversible if thalidomide not discontinued Neutropenia 1, 3 More common in AIDS and BMT recipients Rash 1, 3 More common in AIDS and BMT recipients 
Literature-Supported Oncology and AIDS Indications:
Refractory multiple myeloma 23 Refractory chronic graft-vs -host disease [4] [5] [6] [7] [8] [9] [10] [11] AIDS-related cachexia 12 AIDS-related mucocutaneous ulcers 13, 14 Potential Oncology Uses (requires additional research):
AIDS-related Kaposi's sarcoma 20 -22 Plasma cell leukemia 24 Miscellaneous advanced solid tumors (ie, breast, CNS, prostate) 18, 19, 25, 27, 28, 37, 38 Potential Oncology Uses (potential for new phase I research):
Cancer cachexia 39 Severe, uncontrollable night sweats 40 Combination therapy with anthracyclines (antiangiogenesis and cardioprotective?) 16, 17 Combination therapy with chemotherapy and/ or radiation (antiangiogenesis and effect on mucositis?) 13, 14, 16, 24 Contraindications:
Pregnant women and women capable of becoming pregnant [1] [2] [3] Patients with hypersensitivity to thalidomide 3 AlloBMT recipients without CGVHD 33 Toxic epidermal necrolysis36
Pregnant Women and Women of Childbearing Potential
The critical period of thalidomide-induced teratogenicity occurs between 34 to 50 days after the last menstrual period. 2 A single dose can cause severe birth defects, including absent or defective limbs, hypoplasia or absence of bones, facial palsy, absent or small ears, absent or shrunken eyes, congenital heart defects, and gastrointestinal and renal abnormalities. 2 Unless incapable of childbirth (greater than 12 months from last menstrual cycle or status posthysterectomy), all women on thalidomide therapy must practice two forms of birth control -one highly effective method (intrauterine device, hormonal contraception, partner's vasectomy) and one additional effective barrier method (latex condom, diaphragm, and cervical cap). 3, 29 Ideally, these precautions should begin 4 weeks before initiation of thalidomide and then must continue throughout treatment and at least 4 weeks afterwards.
3,29
Patients must be advised about emergency contraception options if they undergo unprotected sexual intercourse during this time frame. These women must receive pregnancy testing with a sensitivity of at least 50 mIU/mL within 24 hours before initiation, then every week for the next 4 weeks. Thereafter, patients with regular menstrual cycles should be tested monthly, while patients with irregular cycles should be tested every 2 weeks. Pregnancy testing should also be performed if a patient misses her period or if there is any abnormality in menstrual bleeding. 3, 29 As it is unknown whether thalidomide distributes into the male ejaculate, men receiving thalidomide therapy and for 4 weeks afterwards must wear a latex condom during heterosexual intercourse. 3,29 All patients must be advised to never share thalidomide capsules with anyone. If pregnancy does occur during treatment, the drug should be immediately discontinued. Under these conditions, the patient should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure to thalidomide must be reported to the Food and Drug Administration via the MedWatch program at 1-800-FDA-1088 and also to Celgene Corp, the manufacturer of Thalomid.

Nursing Mothers
It is unknown whether thalidomide is excreted in human milk. 3 However, because many drugs are excreted in human milk and because there is the potential for serious adverse reactions from thalidomide in nursing infants, a decision should be made whether to discontinue either nursing or taking the drug, taking into account the importance of the drug to the mother.
HIV-Seropositive Patients With Increased Viral Load
In a randomized, placebo-controlled trial of thalidomide for aphthous ulcers in AIDS patients, plasma HIV mRNA levels were higher in patients receiving thalidomide (median change of 0.42 log 10 copies/mL). 13 This information was acquired prior to use of highly active antiretroviral therapy. While the clinical significance is unknown, HIV viral load should be measured in AIDS patients receiving thalidomide after the first and third months of therapy then every 3 months thereafter.
3
Allogeneic Bone Marrow Transplant Recipients Without Refractory Chronic Graft-vs-Host Disease
Chao et al 33 performed a double-blind, randomized trial with 59 patients to determine whether thalidomide could be used as prophylaxis against CGVHD following allogeneic bone marrow transplantation (alloBMT). Of the 54 evaluable patients, 26 were randomized to placebo and 28 received thalidomide 200 mg po bid beginning on day +80. At the first interim analysis, the thalidomide group surprisingly displayed a higher rate of CGVHD than the placebo group (82% vs 54%, respectively; P=0.06) and a higher mortality (11 in the thalidomide group vs 2 in the placebo group, P=0.0006). Statistical adjustments for possible confounding factors failed to eliminate the negative effect of thalidomide. The authors concluded that thalidomide prophylaxis in alloBMT recipients results in a paradoxical increase in CGVHD.
Patients With Toxic Epidermal Necrolysis
A randomized, placebo-controlled trial of thalidomide 400 mg po qhs for the treatment of toxic epidermal necrolysis demonstrated increased mortality in the thalidomide group (83% vs 30%, P=0.03), possibly due to a paradoxical enhancement of TNF-alpha production. 34 Other Adverse Effects
The most common adverse effects are dose-dependent somnolence and dizziness. 1, 3 To minimize these complications, thalidomide should be administered as a once-daily dose in the evening, if possible. Note that some trials, especially for CGVHD, [4] [5] [6] [7] [8] [9] [10] [11] have studied thalidomide's effectiveness only with multiple daily doses. For indications requiring higher doses, therapy may need to be initiated at low doses (100 to 200 mg/day) and dose-escalated by 100 to 200 mg/day every 1 to 2 weeks to minimize somnolence. 35 Tolerance to sedative properties usually develops over time. Patients should be warned regarding the risks of driving a car or operating heavy machinery while on thalidomide. Patients also should be advised to sit upright for a few minutes prior to standing from a recumbent position due to possible orthostatic hypotension.
Constipation is a common side effect experienced by 3% to 30% of patients at low doses. The constipation is usually mild and responsive to mild laxatives (eg, milk of magnesium, lactulose, psyllium). 3 Consider routine use of stool softeners (docusate) in patients taking thalidomide at 400 mg or more per day. 35 Thalidomide-induced pruritic erythematous macular rash, usually involving the trunk and back, has been reported. 3 The rash usually occurs within 2 to 13 days after initiation and reverses after discontinuation with or without the use of antihistamines. 35 Severe, life-threatening epidermal damage has been reported. 1, 3 Rash is rare (<1%) in patients with Hansen's disease 3 but is more common in patients with CGVHD (16%) 11 and with AIDS (24%). 13 Chronic thalidomide therapy can produce peripheral neuropathy. The neuropathy results from axonal degeneration without demyelination in the sensory fibers of the lower and occasionally upper extremities. Risk of peripheral neuropathy appears to rise with patient age and cumulative dose of thalidomide, resulting in an incidence of approximately 25% in non-lepromatous patients on chronic thalidomide therapy. 35 This toxicity initially presents as numbness of toes and feet then superficial sensory loss in feet and hands. If therapy is not discontinued, the paresthesias of feet and hands will become permanent and will progress proximally. 1, 3 Neutropenia is extremely rare in patients with ENL (<1%) 3 but is considerably more frequent in HIV 13 and CGVHD 11 patients (2% to 20%). Thalidomide should not be initiated when a patient's absolute neutrophil count (ANC) is less than 750 cells/mL. If ANC falls below 750 cells/mL while on treatment, the regimen should be reconsidered. If the ANC falls below 500 cells/mL, thalidomide should be discontinued, with consideration given to filgrastim (G-CSF) therapy. 35 Thalidomide may be resumed when neutropenia resolves, although intermittent use of colony-stimulating factors may be necessary.
Other side effects of thalidomide can include brittle fingernails, decreased libido, endocrine effects (slight depression of thyroid secretion, stimulation of corticotropin and prolactin), face and/or limb edema, increased appetite, menstruation abnormalities, mood changes, nausea, pruritus, red palms, and xerostomia. 1, 3 Drug Interactions
Pharmacokinetic Drug Interactions
Currently, there are no known pharmacokinetic drug interactions with thalidomide. Thalidomide 200 mg/day did not affect the pharmacokinetics of an oral contraceptive containing norethindrone acetate and ethinyl estradiol.
Sedation
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.
Peripheral Neuropathy
Thalidomide should be used cautiously with medications known to cause peripheral neuropathy (eg, cisplatin, paclitaxel, vinca alkaloids).
Important Non-Thalidomide Drug Interactions
Concomitant use of HIV-protease inhibitors, griseofulvin, rifampin, rifabutin, phenytoin, or carbamazepine with hormonal contraceptive agents may reduce their contraceptive efficacy. Other antibiotics such as penicillins, cephalosporins, and tetracyclines may also decrease contraceptive efficacy due to altered estrogen and/or progestin gut metabolism following changes to the intestinal flora. 36 Therefore, women requiring treatment with one or more of these drugs must either use two other effective or highly effective methods of contraception or abstain from reproductive heterosexual intercourse. 3, 29 Thalidomide Uses
Indications Outside Oncology
Thalidomide has been approved by the Food and Drug Administration for the acute treatment of the cutaneous manifestations of moderate to severe ENL. Thalidomide is not indicated as monotherapy for such ENL treatment in the presence of severe neuritis. Thalidomide is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. 3 Tseng et al 1 divided the therapeutic uses of thalidomide into two categories: those with efficacy seen in multiple series (ENL, prurigo nodularis, actinic prurigo, discoid lupus erythematosus, aphthous stomatitis, and Behçet's syndrome) and those with efficacy seen in single series or case reports (palmoplantar pustulosis, sarcoidosis, rheumatoid arthritis, Langerhans cell histiocytosis, pyoderma gangrenosum, uremic pruritus, Jessner-Kanof disease, recurrent erythema multiforme, cold hemagglutination disease, Weber-Christian disease, ulcerative colitis, postherpetic neuralgia, AIDS-associated proctitis, bullous pemphigoid, and cicatricial pemphigoid).
Neoplasms
The role of thalidomide in oncology was first addressed in 1965 by two retrospective reports in the medical literature. Grabstald and Golbey 37 related their experience in 71
patients with a wide spectrum of advanced metastatic malignancies who received daily doses of thalidomide ranging from 300 mg to 2 g. Of these, only one subject demonstrated clinical response -a patient with renal cell cancer who responded with resolution of pulmonary metastases following nephrectomy and 3 months of thalidomide. As spontaneous regression of pulmonary metastases in renal cell cancer following nephrectomy was already well documented, it was unclear from this report whether even this one patient actually benefited from treatment. A second report by Olson et al 38 was slightly more positive. They reported on 21 patients with 14 different types of chemotherapy-unresponsive advanced malignancy. They initiated thalidomide at 200 mg po tid and increased the dose up to 1,400 mg/day as tolerated for 1 to 34 weeks.
No objective evidence of disease regression was obtained. However, 2 patients appeared to benefit from slowing of previously rapid tumor progression. This may have been related to an antiangiogenic effect. Seven patients experienced improved quality of life due to the sedative and anticachetic effects of thalidomide.
Interest in the use of thalidomide in oncology was revived when D'Amato and colleagues 15 demonstrated the ability of orally administered thalidomide to inhibit basic fibroblast growth factor-induced angiogenesis in a rabbit cornea micropocket assay. Experimentation with thalidomide analogs demonstrated that the angiogenesis inhibition correlated with the teratogenicity but not the sedative or immunosuppressive properties of these compounds.
Breast Cancer
Preclinical and limited preliminary human data relating to the antiangiogenic activity of thalidomide were reported by Nguyen et al. 16 Thalidomide monotherapy failed to suppress tumor growth in a murine breast cancer model. In their second experiment, intraperitoneal cyclophosphamide and doxorubicin were administered on day 0 followed by intraperitoneal thalidomide vs saline 3 times weekly beginning on day 1. Therapy began when tumor volumes were less than 50 mm 3 . Primary tumor volume at day 25 was significantly lower in the mice treated with either 200 mg/kg or 300 mg/kg of thalidomide vs mice treated with chemotherapy alone (3,812 mm 3 and 3,432 mm 3 compared with 4,643 mm 3 , respectively; P=0.0005). After 30 days of treatment, 24% of the mice treated with chemotherapy alone developed pulmonary metastases, while none of the mice treated with chemotherapy plus thalidomide had any detected lung or liver metastases. When they repeated the experiment but delayed initiation of the therapy until the primary tumor was greater than 700 mm 3 , the addition of thalidomide to chemotherapy failed to show benefit. One limit to the extrapolation of this animal data is the recent discovery that thalidomide must be hepatically activated to exhibit its antiangiogenic effects and that this active metabolite can be formed in humans and rabbits but not rodents. 30 After completion of their murine studies, Nguyen et al 16 enrolled 7 patients with advanced breast cancer (6 with stage IV) in a phase I trial of thalidomide in combination with conventional cyclophosphamide, doxorubicin, and fluorouracil (CAF). In addition to CAF, these patients received 100 to 300 mg orally at bedtime for 4 weeks. One patient who took 100 mg daily developed a mid rash on her trunk and extremities, while another patient taking 200 mg daily developed worsening constipation; both required early discontinuation. The other patients tolerated therapy well. Three patients had partial responses, 1 had stable disease, 2 progressed, and 1 was lost to follow-up after the rash. Given the limited follow-up time (1 to 6 months) and limited numbers of patients, it is not possible to properly evaluate the response rate of this modality. Of note, thalidomide (and pentoxifylline) may produce cardioprotective effects in subjects receiving doxorubicin according to experimental work with rats by Costa et al. 17 Future studies of thalidomide in combination with anthracyclines are needed to assess this phenomenon in humans.
Thalidomide is under study by Long et al 18 following STAMP1 high-dose chemotherapy (carmustine, cyclophosphamide, and cisplatin) with stem cell rescue for metastatic breast cancer. Thalidomide is initiated at 200 mg po bid beginning at count recovery and continuing until day +180. Currently, 7 of 30 planned patients have been enrolled. All 7 patients experience fatigue with mild somnolence. In addition, 1 patient developed numbness and tingling in the extremities and another experienced a vaso-vagal fainting episode. Doses for patients who tolerate therapy for the first 20 days will be increased to 400 mg po bid. The investigators plan to monitor for adverse effects, potential markers of angiogenesis activity, response rates, and remission duration. 
Central Nervous System Tumors
Kaposi's Sarcoma
Three abstracts have evaluated the use of thalidomide in AIDS-related Kaposi's sarcoma (KS)
600 mg/day experienced headache, and 1 patient at 400 mg/day for 4 months developed paresthesia. Two partial responses were seen (on 200 mg/day and 400 mg/day), and 7 patients had stable disease (2 each on 200, 300, and 400 mg/day; 1 on 600 mg/day). Median time to progression was 4 months, and survival ranged from 4 to 18+ months. Further research at doses of 200 to 300 mg/day is planned.
Yarchoan and associates 22 reported on the effect of thalidomide in 13 patients (8 poor risk and 5 good risk) with AIDS-related KS. Thalidomide was initiated at 200 mg/day and was increased by 200 mg/day on a biweekly basis as tolerated to a maximum dose of 1,000 mg/day. Of the 11 evaluable patients, 4 (36%) achieved partial response, 3 at week 4 and 1 at week 8 at daily doses of 300 mg, 400 mg (2 patients), and 800 mg. Two of the partial responders had not progressed at 30 and 50 weeks, while the other 2 partial responders progressed after 16 and 49 weeks. Two patients suffered from progressive disease after 16 and 24 weeks. The remaining 5 patients exhibited stable disease at date of presentation at 12 weeks (2 patients) and at 22, 32, and 52 weeks. Three patients experienced toxicity (grade 3 rash with fever, myositis, and depression) requiring study discontinuation. Neutropenia (grade 3) and sedation requiring dose reduction occurred in 3 and 5 patients, respectively. Thalidomide appears to be a promising agent for the treatment of AIDS-related KS.
Multiple Myeloma
To date, the best available data on the antiangiogenic activity of thalidomide involve patients with high-risk refractory multiple myeloma. Singhal and associates 23 reported on 89 such patients who received 200 mg/day titrated upward by 200 mg/day every 2 weeks as tolerated to a maximum dose of 800 mg/day. The maximum tolerated dose of thalidomide was continued until disease progression or relapse. This was an extremely chemotherapy-refractory multiple myeloma population in which 78% had more than 24 months of prior therapy, 84% had one stem cell transplant, 63% had multiple stem cell transplants, 66% had cytogenetic abnormalities associated with poor prognosis, and all had disease progression prior to thalidomide treatment. Median duration of therapy was 52 days with 80% having received at least 4 weeks of therapy. Table 3 summarizes the response rates, timing, and duration in those patients who received at least 28 days of thalidomide, as measured by at least monthly M protein analysis of serum and urine.
Median cytoreduction among the 30 responders was 61%. Responses were consistent between high-and low-risk cytogenetics groups. Patients who did not respond within the first 60 days were unlikely to respond with continued therapy. Adverse effects of moderate severity included neurologic (somnolence, dizziness, confusion, tremors, incoordination, tingling, numbness) in 75% of patients, gastrointestinal (constipation, nausea, vomiting, stomatitis) in 66%, and constitutional symptoms (weakness, weight loss, fever) in 60%. Thalidomide was discontinued secondary to toxicity in 8 patients. These results demonstrated impressive salvage activity for thalidomide in highly refractory patients.
Due to the activity detected in these patients with refractory multiple myeloma, many of the same investigators headed by Barlogie 24 evaluated the use of thalidomide in combination with chemotherapy in patients with plasma cell leukemia and fulminant multiple myeloma. Only preliminary data in 10 patients are currently available. These patients received the novel outpatient regimen of D.T.PACE (Table 4) . Of the 5 patients evaluable at the time of abstract release, 3 attained complete response with a single cycle by day 21. Of these, 1 patient had primary refractory plasma cell leukemia with a white blood cell count of >100,000/mm 3 and 2 had fulminant relapse after stem cell transplant. The fourth patient had reduction in lesions identified by magnetic resonance imaging, and the fifth displayed resolution of marrow plasmacytosis and reduction in massive amyloidoma lesions. These 5 patients all had unfavorable chromosome 13 abnormalities. Three responses occurred despite prior resistance to the same chemotherapy regimen without thalidomide. The authors are currently investigating tandem treatment with D.T.PACE and high-dose melphalan.
Prostate Cancer 25 reported preliminary data on the use of thalidomide in 12 patients with metastatic prostate cancer. These patients had failed combined androgen deprivation, and 7 of 12 had failed secondary hormonal therapy. Patients were divided into low (200 mg/day) and high (titration up to 1,200 mg/day) dose levels -6 in each group. Two patients had grade 3 complications (neuromotor and constipation), but other toxicities were mild to moderate. Four patients (2 in each group) had 20% to 37% declines in prostate-specific agent (PSA) -the longest maintained for 84 days. Six patients had progressed at time of publication at 28, 53, 62, 64, 74, and 84 days. The authors plan to enroll 9 patients in each arm of the study with possible extension of one arm based on response. A recent discovery demonstrates that thalidomide use upregulates PSA secretion in the human prostate cell line LNCaP. 26 Future trials of thalidomide for prostate cancer will need to find alternative methods of evaluating response to therapy.
Other Tumors
A phase II trial by Eisen and associates 27 investigated the impact of thalidomide 100 mg po qhs in a variety of advanced solid tumors. Of a total of 48 patients enrolled, 17
had ovarian cancer, 16 had metastatic melanoma, 8 had renal cell carcinoma, and 7 had breast cancer. Three patients had "differential response," while 10 patients demonstrated stable disease for 8 to 25 weeks (median = 12 weeks). Eight patients remained on therapy at the time of publication. Data regarding quality of life indicated an improvement in appetite and sleeping. The investigators were able to correlate changes in serum and urinary vascular endothelial growth factor with response to antiangiogenic treatment. The low dose used in this study may have resulted in suboptimal response to thalidomide.
Marx et al 28 are conducting a phase I/II trial of thalidomide in the treatment of advanced brain, melanoma, breast, colon, mesothelioma, and renal cell carcinoma. Initial response data for 33 patients and toxicity data for 45 patients have been reported in abstract form. Thalidomide was initiated at 100 mg/day but increased weekly in 100 mg/day increments as tolerated to a maximum dose of 500 mg/day. There were no complete responders and only 2 (6%) partial responders. More relevant for an antiangiogenic agent was the 30% incidence of stable disease, although the duration was not reported. The most interesting response data were derived from the 5 patients with glioblastoma, which include the only 2 partial responders and 1 of the patients with stable disease. Thalidomide was reasonably tolerated with this dosing schema with no grade 4 toxicities. Additional trials of this agent in a variety of advanced malignancies are required to determine the range of thalidomide's antioncologic activity.
Chronic Graft-vs-Host Disease
Both animal data 4 and small case reports [5] [6] [7] [8] [9] [10] have provided evidence that thalidomide can produce responses as salvage therapy for refractory CGVHD following alloBMT. The largest reported experience with thalidomide in this setting included 80 patients. 11 Eligibility criteria included progressive CGVHD despite at least 1 month of cyclosporine (CSA) and/or prednisone (31 patients), stable but unimproved CGVHD after at least 2 months of treatment (40 patients), CGVHD that initially responded to standard therapy but flared during immunosuppressant taper requiring a daily dose of at least 20 mg of prednisone (7 patients), or prednisone therapy that was medically contraindicated (2 patients). While prior CSA therapy was not required, 67 patients had CSA-resistant disease, while 13 patients were unable to receive further CSA due to excessive CSArelated end-organ toxicity. A total of 38 patients had high-risk CGVHD as indicated by the presence of thrombocytopenia, progressive CGVHD, and/or CGVHD of the skin and liver. Thalidomide was initiated at 100 mg po qid, then the dose was gradually escalated to 200 to 300 mg po qid as tolerated. Patients were maintained on prednisone and CSA when thalidomide started, but these were slowly tapered in patients whose condition responded to thalidomide. The overall response rate was 20%, with 9 complete responses (CRs) and 7 partial responses (PRs). High-risk CGVHD responded in 16% of cases (4 CRs and 2 PRs in 38 patients), while standard-risk CGVHD responded in 24% (5 CRs and 5 PRs in 42 patients). Responses were rare for bronchiolitis obliterans with obstructive pneumonia, combined skin and liver CGVHD, and progressive presentation. Most responses were seen in patients with isolated oral or liver CGVHD and skin involvement without severe scleroderma. Sedation was the most common side effect (40%), followed by constipation/nausea (30%), neutropenia (18%), new skin rash (16%), and neuritis (5%). Thalidomide was discontinued in 36% of patients due to toxicity. Side effects also prevented maximal dose escalation; few patients tolerated doses of much greater than 400 to 600 mg/day. Thalidomide has a role in refractory CGVHD due to a dearth of effective therapies for this complication of alloBMT.
Cachexia
Cachexia is a constellation of symptoms encountered in patients with cancer and end-stage AIDS -anorexia, early satiety, chronic nausea, asthenia, and a catabolic state resulting primarily in loss of lean body mass. Cachexia results from a complicated interaction of tumor effects, treatment effects, and host cytokines including TNF-alpha. 39 Due to its anti-TNF-alpha activity, thalidomide was studied in 28 patients with advanced AIDS with wasting syndrome. 12 These patients were adult AIDS patients with progressive loss of more than 10% body weight within the previous 6 months despite at least 12 weeks of antiretroviral therapy, as well as CD4+ T cells of less than 500 x 10 6 /L and a Karnofsky performance index of more than 50%. Patients could not receive concurrent immunosuppressants, megestrol acetate, pentoxifylline, or parenteral or enteral nutrition. Patients were stratified by severity of weight loss and CD4+ T-cell counts and then randomized to receive either thalidomide 100 mg po q6h (14 patients) or placebo (14 patients) for 12 weeks. Clinical efficacy was defined as more than 5% weight gain in at least 3 consecutive measurements or no progression of the wasting syndrome (more than 5% weight decline). Treatment failure included progressive wasting, severe drug toxicity, noncompliance, voluntary withdrawal, or death. After 12 weeks, 71% of the 14 patients in the placebo group failed due to progressive wasting (9 patients) or toxicity (1 patient). In the thalidomide-treated group, 21% of the 14 patients had failed due to progressive wasting (1 patient) or toxicity (2 patients). Also in this group, 8 patients exhibited weight gain compared with only one in the placebo group. Patients with weight gain demonstrated increases in not only fatty tissue, but also muscle mass. Median Karnofsky index remained stable in patients on thalidomide (80%) but fell in placebo subjects (80% to 60%). No effect on HIV viral burden or CD4+ T-cell counts was detected. In the thalidomide-treated group, transient somnolence occurred in 11 patients and skin rash also in 11 patients, whereas in the placebo group, transient somnolence was seen in 5 patients and skin rash in 3. One patient in the thalidomide group experienced a severe skin rash that was life-threatening, and 1 patient developed peripheral neuropathy. Due to similarities in clinical presentation and probable mechanism between AIDS-related and cancer-induced cachexia, clinical trials of thalidomide in patients with cancer cachexia are warranted.
Night Sweats
A 59 year-old man with severe, drenching night sweats induced by mesothelioma was unresponsive to prednisone 25 mg po qd and diclofenac 50 mg po tid. However, he did respond to thalidomide 200 mg po qhs. 40 The night sweats almost completely ceased within 3 days but rapidly returned within 24 hours of the end of his 14-day trial. He was then restarted at 100 mg po qhs with rapid response. The effectiveness of thalidomide in patients with severe night sweating that results in reduced quality of life should be investigated further.
Stomatitis
Thalidomide has not been evaluated for the prevention or amelioration of chemotherapy-or radiation-induced mucositis. However, thalidomide has demonstrated efficacy in HIV-infected patients with oral aphthous ulcers 13 and idiopathic esophageal ulcers. 14 In the oral ulceration trial, 16 (55%) of 29 patients had complete healing after 4 weeks of thalidomide 200 mg po qhs vs 2 (7%) of 28 patients in the placebo group. The thalidomide group also experienced reduced oral pain and improved ability to eat. Twelve patients with idiopathic esophageal ulcers were treated with thalidomide 200 mg po qhs resulting in a 92% complete symptomatic response. 14 Prospective, double-blind, placebo-controlled trials will need to be performed to evaluate whether thalidomide can reduce chemotherapy-or radiation-induced mucositis in oncology patients.
Dosage and Administration
Erythema Nodosum Leprosum
For an episode of cutaneous ENL, therapy should be initiated at 100 to 300 mg po qhs. Patients weighing less than 50 kg should be started at the low end of the dosing range. Patients with severe cutaneous ENL or those who have previously required higher doses to control the reaction may be started at 400 mg po qhs. In patients with severe neuritis associated with a severe ENL reaction, corticosteroids may be started concomitantly with thalidomide, then tapered off when neuritis resolves. Thalidomide therapy should be continued until signs and symptoms of active reaction have subsided (usually after a period of at least 2 weeks) then tapered off in 50 mg decrements every 2 to 4 weeks. Patients with a documented history of requiring prolonged maintenance therapy should be maintained on the minimal possible dose. Tapering off the medication should be attempted every 3 to 6 months in decrements of 50 mg every 2 to 4 weeks.
3
Antitumor Activity A wide range of doses (100 to 1,200 mg/day) and dosing schedules (qhs to qid) continue to be studied in a variety of tumor types. Whether there is a dose-response relationship for activity is unknown, although there is a relationship for toxicity. 35 Clinicians planning to use thalidomide in this setting are encouraged to enter their patients into clinical trials whenever possible. If study enrollment is not possible, clinicians should use generally the same dosing schema for which safety and efficacy data are available in patients with the same disease state.
Refractory Chronic Graft-vs-Host Disease
While optimal dosing for the treatment of CGVHD was not been established, clinicians should prescribe this agent based on the available literature. One approach is to initiate therapy at 100 mg po qid. The thalidomide dose should then be titrated upward gradually to a goal dose of 200 to 300 mg po qid based on the patient's tolerance and evidence of clinical response. 11 
Cost Evaluation
Thalidomide is supplied in boxes of 6 prescription packs of 14 capsules consisting of 50 mg each. Currently, the average wholesale price (AWP) for each box of 84 capsules is $630, which equals $7.50 per capsule. 41 Daily costs per dose are shown in Table 5 .
Special Requirements
To minimize the substantial risk of thalidomide-induced teratogenicity -and with the approval of the Food and Drug Administration -Celgene Corp requires prescribers, pharmacists, and patients to use a restricted distribution system: the System for Thalidomide Education and Prescribing Safety (STEPS). 3, 29 To prescribe thalidomide, the physician, physician assistant, or advanced registered nurse practitioner must register with the STEPS program. To dispense thalidomide, the pharmacy must also be registered with the STEPS program. Patient education materials on the risks of thalidomide and on contraceptive measures are required to be reviewed with the patient. The patient and the prescriber are then required to review and sign the informed consent form. The consent form informs the patient of necessary contraceptive measures and frequency of pregnancy testing, as discussed previously. Patients are also required to participate in a mandatory and confidential survey on a monthly basis for women and at least every 3 months for men. The registered pharmacy may dispense no more than a 28-day supply of thalidomide after receiving a copy of the informed consent document and after electronically verifying patient and prescriber eligibility with the STEPS Patient Registry. As most inpatient hospital pharmacies are unlikely to participate in the STEPS program, patients should bring their own supply of thalidomide if hospitalization is required.
Conclusions
Thalidomide is a complex immunomodulatory and antiangiogenic agent whose role in oncology practice is as yet not fully clear. Thalidomide has notable salvage therapy in multiple myeloma and CGVHD following alloBMT. To determine its antiangiogenic activity and how best to use this agent, thalidomide needs to be studied in a variety of tumor types, used both alone and in combination with chemotherapy. Whenever possible, patients with refractory malignancies should be enrolled in clinical trials to answer some of these questions. In addition, further research may indicate whether thalidomide has a beneficial role in reducing or preventing cancer cachexia and mucositis. The potential benefits of thalidomide must not blind us to the danger of teratogenicity. Proper patient counseling and monitoring are critical for the safe use of thalidomide in the oncology population. 
